Related Experiment Videos
[Basic and clinical studies on serum CEA levels using a new CEA-EIA (double monoclonal) kit]
Gan No Rinsho. Japan Journal of Cancer Clinics
|December 1, 1984
Summary
A new double monoclonal kit for measuring serum carcinoembryonic antigen (CEA) shows superior reproducibility and stability compared to older kits. This CEA assay effectively identifies malignant diseases, particularly gastrointestinal and pancreatic cancers.
Area of Science:
- Oncology
- Biochemistry
- Immunodiagnostics
Context:
- Serum Carcinoembryonic Antigen (CEA) is a biomarker used in cancer diagnostics.
- Existing CEA assays have limitations in reproducibility and stability.
- A novel double monoclonal enzyme immunoassay (EIA) kit for CEA has been developed.
Purpose:
- To evaluate the performance of a new Abbott CEA-EIA (double monoclonal) kit.
- To compare the new CEA assay with a polyclonal CEA kit.
- To assess the diagnostic utility of the new CEA kit in normal subjects and patients with benign and malignant diseases.
Summary:
- The new double monoclonal CEA-EIA kit demonstrated high correlation (r=0.976) with a polyclonal CEA kit.
- The new kit exhibits superior reproducibility, stability, and simplicity.
- Elevated CEA levels (>7.0 ng/ml) were detected in 24.1% of patients with malignant diseases, with high positive rates in biliary tract, pancreas, colon, esophagus, and stomach neoplasms.
Impact:
- This improved CEA assay offers enhanced diagnostic accuracy for various cancers.
- The kit's superior performance facilitates more reliable monitoring of cancer patients.
- Clinical application of this sensitive CEA detection method can aid in early cancer diagnosis and management.